MEDICINA

2024

1. ANCHOR: melflufen plus dexamethasone and daratumumab or bortezomib in relapsed/refractory multiple myeloma: final results of a phase I/IIa study

   Haematologica, Vol. 109, Núm. 3, pp. 867-876

2. Aggressive systemic mastocytosis with the co-occurrence of PRKG2::PDGFRB, KAT6A::NCOA2, and RXRA::NOTCH1 fusion transcripts and a heterozygous RUNX1 frameshift mutation

   Cancer Genetics, Vol. 284-285, pp. 5-11

3. Albumin Redox Modifications Promote Cell Calcification Reflecting the Impact of Oxidative Status on Aortic Valve Disease and Atherosclerosis

   Antioxidants, Vol. 13, Núm. 1

4. An interesting dance couple in a Sub-saharan immigrant

   Enfermedades Infecciosas y Microbiologia Clinica

5. Artificial intelligence-derived risk score for mortality in secondary mitral regurgitation treated by transcatheter edge-to-edge repair: The EuroSMR risk score

   European Heart Journal, Vol. 45, Núm. 11, pp. 922-936

6. Assessing the Effectiveness of Textual Recommendations in KoopaML: A Comparative Study on Non-Expert Users' ML Pipeline Development

   International Journal on Semantic Web and Information Systems, Vol. 20, Núm. 1

7. Bicaval TricValve Implantation in Patients With Severe Symptomatic Tricuspid Regurgitation: 1-Year Follow-Up Outcomes

   JACC: Cardiovascular Interventions, Vol. 17, Núm. 1, pp. 60-72

8. CLO24-079: Results From Phase 3 Trial of Imetelstat, a First-in-Class Telomerase Inhibitor, in Patients With Red Blood Cell Transfusion Dependent (RBC-TD) Non-del(5q) Lower-Risk Myelodysplastic Syndromes (LR-MDS) Relapsed/Refractory to/Ineligible for Erythropoiesis Stimulating Agents (ESAs)

   Journal of the National Comprehensive Cancer Network : JNCCN, Vol. 22, Núm. 25

9. COMPLICATIONS SECONDARY TO THE USE OF SGLT2 INHIBITORS IN ONCOLOGICAL PATIENTS: A SERIES OF 5 CASES

   European Journal of Case Reports in Internal Medicine, Vol. 11, Núm. 1

10. Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 24, Núm. 4, pp. 224-231.e2

11. Characterizing the “iceberg peak” in valvular heart disease: Outcomes and costs of in-hospital procedures in Spain

    REC: CardioClinics

12. Chromosomal breaks: another differential gap between early-onset and late-onset colorectal cancers

    British Journal of Surgery, Vol. 111, Núm. 3

13. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 79, Núm. 3, pp. 711-723

14. Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 2, pp. 696-715

15. Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma

    Advances in Therapy, Vol. 41, Núm. 4, pp. 1576-1593

16. Comparison of Clinical and Genetic Characteristics Between Younger and Older Lung Cancer Patients

    Archivos de Bronconeumologia, Vol. 60, Núm. 2, pp. 88-94

17. Consenso del grupo de trabajo de los trastornos de la conducta alimentaria de SENPE (GTTCA-SENPE). Evaluación y tratamiento médico-nutricional en la anorexia nerviosa. Actualización 2023

    Nutricion hospitalaria, Vol. 41, Núm. 1, pp. 1-60

18. Covering Hierarchical Dirichlet Mixture Models on binary data to enhance genomic stratifications in onco-hematology

    PLoS Computational Biology, Vol. 20, Núm. 2

19. Current challenges in cell and gene therapy: a joint view from the European Committee of the International Society for Cell & Gene Therapy (ISCT) and the European Society for Blood and Marrow Transplantation (EBMT)

    Cytotherapy

20. Cutaneous T-Cell Lymphoma and Microbiota: Etiopathogenesis and Potential New Therapeutic Targets

    Dermatology Research and Practice, Vol. 2024